Photochromic lens innovations fuel consumer demand

Article

Innovations in photochromic lens technology, combined with wider availability through mass merchandisers, have revitalized the sector during the past few years.

Key Points

"We're definitely seeing an increase in the popularity of photochromic lenses as the technology has advanced," Main said. Significant improvements, such as the indoor clarity of the lens and the speed of change, are gaining wider acceptance for the product among patients and eye-care professionals (ECPs) alike, he added.

Transitions, established in 1990, is a leader in the photochromic lens arena.

Innovations coupled with greater availability through mass merchandisers have revitalized the sector over the past few years, he added.

Advances improve performance

According to company data, it is as clear indoors as a clear lens and fades back to clear 30% to 40% faster than previously available lenses.

"This is the first generation to work uniformly across all lens materials," he added. The lens reportedly gets 10% to 15% darker in hotter temperatures compared with Transitions V, and it is darker in moderate temperatures than previous generations.

These properties are enhanced when photochromics are combined with an anti-reflective (AR) coating. With the addition of AR coating, lenses fade back to clear 30% faster and are 6% clearer indoors and at night, according to the company.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.